Organization | Innovation Fund Denmark

Innovation Fund Denmark Report issue

Foundation Phase 1 Phase 3 Phase 4

Founded: Aarhus Denmark (2014)

Organization Overview

First Clinical Trial

2016

NCT02829697

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Innovation Fund Denmark

Active Ingredients

Drugs in Phase 4 Trials (4)

ceftriaxone (rocephin) (1 trial)

co-amoxiclav (1 trial)

dicloxacillin (pathocil) (1 trial)

ropivacaine (naropin) (3 trials)

Drugs in Phase 3 Trials (1)

iloprost (ventavis) (1 trial)

Drugs in Phase 1 Trials (1)

lidocaine (xylocaine) (1 trial)

Drugs in Other Trials (5)

barley (2 trials)

calcium (1 trial)

calcium carbonate (1 trial)

human fecal microbiota (Reybota) (1 trial)

wheat (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis, Infectious (Phase 4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Osteomyelitis (Phase 4)

Pain, Postoperative (Phase 4)

Shock (Phase 3)

Shock, Septic (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 11